Lipidomics Update
... 1. Zhenwen Zhao, Yan Xu, An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples. J Lipid Res, 2010, 51: 652-659. PMID: 19783525. 2. Zhenwen Zhao, Yan Xu, Accurate measurement of lysophosphatidic acid by ESIMS/MS in plasma samples requires preseparation of ...
... 1. Zhenwen Zhao, Yan Xu, An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples. J Lipid Res, 2010, 51: 652-659. PMID: 19783525. 2. Zhenwen Zhao, Yan Xu, Accurate measurement of lysophosphatidic acid by ESIMS/MS in plasma samples requires preseparation of ...
Non-Small Cell Lung Cancer (NSCLC)
... 1. Cagle, PT, and Dacic, S, Lung Cancer and the Future of Pathology. Arch Pathol Lab Med 2011; 135:293-5. 2. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (Version 2.2013). ©National Comprehensive Cancer Network, Inc. 2013. 3. Grilley-Olson, J, et al., Validation o ...
... 1. Cagle, PT, and Dacic, S, Lung Cancer and the Future of Pathology. Arch Pathol Lab Med 2011; 135:293-5. 2. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (Version 2.2013). ©National Comprehensive Cancer Network, Inc. 2013. 3. Grilley-Olson, J, et al., Validation o ...
Genomic comparison of paired primary breast
... tumor and the nodal deposit. These results may further our understanding of tumor heterogeneity and biological sensitivity in the process of lymph node metastasis and ultimately systemic metastases. Methods: We examined the formalin fixed paraffin embedded tumor tissues (FPET) from 100 breast cancer ...
... tumor and the nodal deposit. These results may further our understanding of tumor heterogeneity and biological sensitivity in the process of lymph node metastasis and ultimately systemic metastases. Methods: We examined the formalin fixed paraffin embedded tumor tissues (FPET) from 100 breast cancer ...
PRESS STATEMENT DIRECTOR GENERAL OF HEALTH
... (16.3%), lung (15.8%), nasopharynx (8.1%), lymphoma (6.8%) and prostate (6.7%). Among females, the five most common were cancers of the breast (32.1%), colorectum (10.7%), cervix uteri (7.7%), ovary (6.1%) and lung ...
... (16.3%), lung (15.8%), nasopharynx (8.1%), lymphoma (6.8%) and prostate (6.7%). Among females, the five most common were cancers of the breast (32.1%), colorectum (10.7%), cervix uteri (7.7%), ovary (6.1%) and lung ...
6654
... lung cancers are of non-small cell histology, for which prognosis depends primarily upon tumor stage at the time of diagnosis. Although overall survival rates with non-small cell carcinoma are dismal, patients with surgical stage I disease may have 10-year survivals of up to 70%. This has formed the ...
... lung cancers are of non-small cell histology, for which prognosis depends primarily upon tumor stage at the time of diagnosis. Although overall survival rates with non-small cell carcinoma are dismal, patients with surgical stage I disease may have 10-year survivals of up to 70%. This has formed the ...
Table 4. The Revised Bethesda Guidelines for Testing
... with HNPCC- related tumors regardless of the age. *colorectal carcinoma, endometrial carcinoma, and other related cancer: small bowel, transitional cell carcinoma of the upper urinary tract, stomach, ovarian, brain( Turcot syndrome) and sebaceous gland adenomas or keratoachantomas ( Muir-Torre sundr ...
... with HNPCC- related tumors regardless of the age. *colorectal carcinoma, endometrial carcinoma, and other related cancer: small bowel, transitional cell carcinoma of the upper urinary tract, stomach, ovarian, brain( Turcot syndrome) and sebaceous gland adenomas or keratoachantomas ( Muir-Torre sundr ...
WE GMC presentation_May 2016
... 1. Complete whole genome sequencing of 4,650 samples from patients and families. ...
... 1. Complete whole genome sequencing of 4,650 samples from patients and families. ...
Supplemental Figures 1 to 11
... green boxes, respectively. (B) GSVA of gene sets related to Tight junctions, Arginine/Proline Metabolism, Cholesterol/Steroid synthesis, and glucose metabolism from the REACTOME (R) and KEGG (K) databases. (C) GSVA of gene sets related to Cholesterol/Steroid synthesis, and glucose metabolism from th ...
... green boxes, respectively. (B) GSVA of gene sets related to Tight junctions, Arginine/Proline Metabolism, Cholesterol/Steroid synthesis, and glucose metabolism from the REACTOME (R) and KEGG (K) databases. (C) GSVA of gene sets related to Cholesterol/Steroid synthesis, and glucose metabolism from th ...
bioinformatician job opportunity- Gabut
... The Gabut team combines multi-‐disciplinary approaches (clinical, cellular, molecular and transcriptomics) in order to : -‐ characterize CSCs responsible for glioblastomas ; -‐ Identify new markers of CSCs ; ...
... The Gabut team combines multi-‐disciplinary approaches (clinical, cellular, molecular and transcriptomics) in order to : -‐ characterize CSCs responsible for glioblastomas ; -‐ Identify new markers of CSCs ; ...
Short congress report from AACR.NCI.EORTC
... National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, gathered approximately 3,000 academics, scientists, and pharmaceutical industry representatives from across the globe. At the meeting new anti-cancer targets and drug mechanisms of action were presented. H ...
... National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, gathered approximately 3,000 academics, scientists, and pharmaceutical industry representatives from across the globe. At the meeting new anti-cancer targets and drug mechanisms of action were presented. H ...
Supplemental information Validation of Lehmann et al.`s Gene
... patients’ DNA microarrays) from their TNBC validation set. All of the arrays used were a type of Affymetrix U133 array: U133A, U133 Plus 2.0, or U133AAofAv2. Lehmann et al. used the robust multiarray average (RMA) algorithm to normalize and quantify the data. The data pre-processing and quantificati ...
... patients’ DNA microarrays) from their TNBC validation set. All of the arrays used were a type of Affymetrix U133 array: U133A, U133 Plus 2.0, or U133AAofAv2. Lehmann et al. used the robust multiarray average (RMA) algorithm to normalize and quantify the data. The data pre-processing and quantificati ...
Παρουσίαση του PowerPoint
... [18], comprised of 60 samples (9 controls and 51 BC samples); 3) GSE7476 dataset [19], composed of 12 samples (3 controls and 9 BC samples) and 4) GSE12630 dataset, comprised of 19 BC samples. In total, our pooled microarray analysis was composed of 17 control samples (n=5, for the CodeLink platform ...
... [18], comprised of 60 samples (9 controls and 51 BC samples); 3) GSE7476 dataset [19], composed of 12 samples (3 controls and 9 BC samples) and 4) GSE12630 dataset, comprised of 19 BC samples. In total, our pooled microarray analysis was composed of 17 control samples (n=5, for the CodeLink platform ...
GSI_2015_Kartha
... therapeutics. Here, we perform a multi-omic investigation using a combination of OSCC cell-line gene expression profiles and massive public genomic data to help determine potential mechanisms driving OSCC pathogenesis. Gene expression signatures pertaining to genetic knockdowns of DPAGT1 - a gene cr ...
... therapeutics. Here, we perform a multi-omic investigation using a combination of OSCC cell-line gene expression profiles and massive public genomic data to help determine potential mechanisms driving OSCC pathogenesis. Gene expression signatures pertaining to genetic knockdowns of DPAGT1 - a gene cr ...
The Urology Clinic of "Prof. Dr. Th. Burghele" Clinical Hospital
... 3. Elucidating the biological mechanisms that cause increased risk of prostate cancer. Project CAGEKID CAGEKID project (CAncer GEnetics of KIDney) is developed by an international scientific consortium coordinated by the Agency for Cancer Studies at Lyon (IARC) for a period of three years. Of all ca ...
... 3. Elucidating the biological mechanisms that cause increased risk of prostate cancer. Project CAGEKID CAGEKID project (CAncer GEnetics of KIDney) is developed by an international scientific consortium coordinated by the Agency for Cancer Studies at Lyon (IARC) for a period of three years. Of all ca ...
Yu Shyr, PhD
... This paper provides a checklist of criteria that can be used to determine the readiness of omics-based tests for guiding patient care in clinical trials. The checklist criteria cover issues relating to specimens, assays, mathematical modeling, clinical trial design, and ethical, legal and regula ...
... This paper provides a checklist of criteria that can be used to determine the readiness of omics-based tests for guiding patient care in clinical trials. The checklist criteria cover issues relating to specimens, assays, mathematical modeling, clinical trial design, and ethical, legal and regula ...
Personal Genome Diagnostics Awarded National Cancer Institute
... BALTIMORE, MD, February 1, 2017 – Personal Genome Diagnostics Inc. (PGDx) today announced that it has been awarded an SBIR contract from the National Cancer Institute (NCI) for the development of a novel diagnostic to help identify patients who are most likely to benefit from treatment with immuno-o ...
... BALTIMORE, MD, February 1, 2017 – Personal Genome Diagnostics Inc. (PGDx) today announced that it has been awarded an SBIR contract from the National Cancer Institute (NCI) for the development of a novel diagnostic to help identify patients who are most likely to benefit from treatment with immuno-o ...
A Promising Project - Medidata Solutions
... Geoff Low: Genomics focuses on the analysis of the genome – the order of a complete set of DNA located within the individual cells of an organism. Advances in molecular sequencing and bioinformatics technology have driven this approach, which goes well beyond the gene-based view of genetics towards o ...
... Geoff Low: Genomics focuses on the analysis of the genome – the order of a complete set of DNA located within the individual cells of an organism. Advances in molecular sequencing and bioinformatics technology have driven this approach, which goes well beyond the gene-based view of genetics towards o ...
TACMASS Usage Agreement - The University of Arizona Cancer
... Please acknowledge this shared service for any published material or grants. Continued funding for all the Shared Services from the AZCC Support Grant is dependent upon citations and publications arising from our services. TACMASR Usage Agreement Use of data produced by the TACMASR Core (Tissue Acqu ...
... Please acknowledge this shared service for any published material or grants. Continued funding for all the Shared Services from the AZCC Support Grant is dependent upon citations and publications arising from our services. TACMASR Usage Agreement Use of data produced by the TACMASR Core (Tissue Acqu ...
Personal Genome Diagnostics Study Highlights Limitations of Tumor
... realizing the potential of personalized medicine to achieve better treatment outcomes. As a result of this work, we decided to include the option to analyze both normal and tumor tissue DNA when we launched our TM CancerSelect targeted gene panel, which is designed to detect those genetic alteration ...
... realizing the potential of personalized medicine to achieve better treatment outcomes. As a result of this work, we decided to include the option to analyze both normal and tumor tissue DNA when we launched our TM CancerSelect targeted gene panel, which is designed to detect those genetic alteration ...
PPT Version - OMICS International
... oncogenomics which has been informative. Genes of the same family have similar functions, as predicted by similar coding sequences and protein domains, have been systematically sequenced in cancerous genomes to identify particular pathways which may be associated with cancer progression. Drug therap ...
... oncogenomics which has been informative. Genes of the same family have similar functions, as predicted by similar coding sequences and protein domains, have been systematically sequenced in cancerous genomes to identify particular pathways which may be associated with cancer progression. Drug therap ...
PPT - International Cancer Genome Consortium
... and ICD-O). If novel molecular subtypes are studied, these should be defined with sufficient detail. All samples will have to be reviewed by two or more reference pathologists. ...
... and ICD-O). If novel molecular subtypes are studied, these should be defined with sufficient detail. All samples will have to be reviewed by two or more reference pathologists. ...
The Genetics of Cancer: Is Personalization of Cancer Treatment
... need to have large numbers of targeted treatments • Tumor biopsies & sequencing at progression to ...
... need to have large numbers of targeted treatments • Tumor biopsies & sequencing at progression to ...
Title of the research project: _
... One of the major goals of oncology is to predict the response of patients with cancer to chemotherapeutic agents by employing laboratory methods called tumour chemosensitivity assays. The aim of the project is to evaluate usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromid ...
... One of the major goals of oncology is to predict the response of patients with cancer to chemotherapeutic agents by employing laboratory methods called tumour chemosensitivity assays. The aim of the project is to evaluate usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromid ...